Simcere Partners Up with Suzhou NeuPharma on Cancer Drug

Simcere, a China biopharma that is expanding from its branded generic drug base with numerous innovative research collaborations, signed a strategic cooperation agreement with Suzhou NeuPharma to develop and produce novel drugs. The first candidate is a cancer drug. Simcere will contribute its production and marketing expertise, while NeuPharma will be responsible for developing drug candidates. More details.... Stock Symbol: (NYSE: SCR)